Fortrea (NASDAQ:FTRE) agreed on September 2, 2026 to acquire Worldwide Clinical Trials’ Early Phase Services division in an all-cash transaction valued at approximately $45 million.
Fortrea (NASDAQ:FTRE) appointed Jason Knoblauch as Chief Financial Officer, effective July 6, 2026.
Fortrea Holdings (NASDAQ:FTRE) reported second-quarter 2026 revenue of $678.2 million, compared to $710.3 million in the same period last year.
Fortrea (NASDAQ:FTRE) reported a steady start to 2026, characterized by robust new business wins and a growing backlog that provides a solid foundation for the company as it navigates its second full year as a standalone clinical research organization (CRO).
